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SUMMARY The effect of loperamide and naloxone on mouth-to-caecum transit time was
evaluated by the lactulose hydrogen breath test in four men and four women. Each subject
underwent tests during the administration of placebo, loperamide (12-16 mg po), naloxone (40
,ug/kg/h by a three-hour intravenous infusion), and loperamide plus naloxone, carried out at
intervals of one or two weeks. The transit time was significantly longer after loperamide, and this
effect was antagonised by the concomitant administration of naloxone whereas naloxone
administered alone had no effect on mean transit time. No clinically important side effects were
reported.
Morphine changes the motility pattern in the gastro-
intestinal tract,' decreases the propulsion of its
contents,2 3 reduces gastric4 and intestinal
secretions5 and increases water and ions
absorption.6 7 Loperamide, an opioid agonist,
retains most peripheral effects of morphine, many of
which are inhibited by the opioid antagonist
naloxone,8 but is nearly devoid of its central nervous
system activity.
In patients with irritable bowel syndrome
loperamide slows the small bowel transit of a meal9
and increases orocaecal transit time as measured by
lactulose hydrogen breath test. 10 The reproducibility
of this simvle, non-invasive test has recently been
questioned " and it has been reported to be
influenced by sex12 and menstrual cycle phases;13
however, Morley et al14 found it adequate to detect
the increase of gastrointestinal transit time caused
by gluten peptides which are believed to have an
opioid-like activity, and the inhibition of this effect
by naloxone.
In rats, the opioid antagonists naloxone and
N-methylnaloxone have been shown to reverse the
morphine-induced increase in gastrointestinal
transit time assessed by measuring the length of
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bowel traversed by a charcoal test meal. '5 The
present study was designed to assess in healthy
human subjects of both sexes the effect of
loperamide and naloxone on orocaecal transit time
measured by the hydrogen breath test.
Methods
SUBJECTS
Eight healthy volunteers (four men, age range 25-34
years, mean age 28 years, weight 72, 69, 68, and 64
kg; four women, age range 23-26 years, mean age 25
years, weight 72, 50, 49, and 48 kg) were studied
after having given their informed consent. All
volunteers belonged to the medical staff of the clinic
and were willing to comply with the conditions
needed for the test.
The weekly number of bowel movements was five
to 10 in six subjects, three to four in one woman and
two to three in another woman. None of the subjects
took any medication for at least 72 hours or any
antibiotics for at least two months before the
beginning of the study, or during it. Subjects were
asked to have a standard meal consisting of one
serving of boiled rice, a steak, and water ad libitum
at 8 pm the day before the test. Then they did not
take anything except for the treatments. Smoking
was not allowed between midnight and the end of
the test. Studies were performed in a quiet
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environment, subjects being at complete rest.
Orocaecal transit time was assessed by means of
the hydrogen breath test.16 At 9 30 am the fasting
subjects ingested 10 g lactulose (Duphalac Philips
Duphar, Weesp, Holland, 15 ml) suspended in 100
ml tap water. End expiratory breath samples were
obtained just before and every 10 minutes after the
ingestion of lactulose using a modified Haldane-
Priestley tube. 17 Samples were immediately
analysed for molecular hydrogen using a
chromatograph with a thermal conductivity detector
(mod. 3200 DANI, Monza, Italy) as described by
Zuccato et al.18 Values were expressed as ppm
corresponding to 0 045 ,umol/l. The mean of 12
determinations of standard samples containing 50
ppm H2 were 50 5 ppm±3-17 SD. The r values of
calibration curves obtained from standard samples
of H2 (2-100 ppm) were 0 994.
Orocaecal transit time was defined as the time
elapsing between ingestion of lactulose and the first
definite and sustained rise of breath hydrogen
concentration - that is, an increase of at least 2 ppm
above the baseline, maintained or increased in the
three following determinations. Hydrogen breath
tests were carried out for at least three hours or until
the orocaecal transit time was determined.
Orocaecal transit time was assessed by a physician
not aware of the treatments.
The subjects were divided into two blocks
according to sex; each subject was studied on four
separate occasions at intervals of one or two weeks.
Each time a different treatment (A, B, C or D) was
given, the sequence being as follows: subject 1,
CADB; subject 2, ABCD; subject 3, BDAC;
subject 4, DCBA; subject 5, BCDA; subject 6,
DCBA; subject 7, BDAC; subject 8, CABD. The
treatments were known only to the physician in
charge of administering them. The treatments were
administered as follows: at 10 pm the day before and
at 8 30 am on the day of the test the five subjects
weighing over 50 kg were given four capsules and
the remaining three subjects three capsules with a
sip of tap water. On the day of the test from 9-9 30
am each subject was given an intravenous infusion
of saline 100 ml, and from 9 30 am-12 30 pm, while
the hydrogen breath test was carried out, a further
intravenous infusion of saline 500 ml with or without
the study drug. If the hydrogen breath test was not
stopped at 12 30 a further intravenous infusion of
saline (with or without the study drug) was given
until the end of the test.
Treatment A consisted of placebo infusion and
placebo capsules, treatment B of placebo infusion
and loperamide capsules, treatment C of naloxone
infusion and placebo capsules, and treatment D of
naloxone infusion and loperamide capsules.
Loperamide (Lopemid Gentili, Pisa, Italy) was
given as capsules of 2 mg each and naloxone
hydrochloride (Narcan Crinos, Villa Guardia, Italy)
was given at doses of 40 gg/kg/h.
Symptoms and bowel movements during the 48
hours after the start of the test were recorded as well
as the day of the menstrual cycle. The female
subjects were not on oral contraceptives; four of the
16 tests on these subjects were undertaken during
the luteal phase of the menstrual cycle.
Statistical analysis was performed with split-plot
design (between-within subjects ANOVA) followed
by Tukey's test for multiple comparisons19 and
Fisher's exact test for frequency data.
Results
The orocaecal transit time in each subject according
to treatments and the results of the analysis of
variance are reported in the Table.
The difference in transit time between sexes was
not statistically significant. In men and women
loperamide prolonged transit time in comparison
with the other treatments (Tukey's test: p<005)
while transit times during naloxone and loperamide
plus naloxone administration were not statistically
different from placebo or from each other. Only in
subject 7, who had two to three bowel movements
per week, transit time was not affected by
loperamide and was reduced by naloxone.
During the 48 hours after the start of the test there
Table Orocaecal transit time in minutes according to
treatments in 4 males and 4females
Treatments
A B C D
Placebo Loperamide Naloxone Loperamide
+ naloxone
Men
1 90 180 90 90
2 60 110 60 80
3 60 200 70 50
4 50 140 50 40
mean 65-0 157-5 67.5 65-0
SD 17.3 40-3 17-1 23-8
Women
5 50 90 30* 50
6 80* 170 80 60
7 140* 140* 100 150
8 120 220 130 120
mean 97-5 155.0 85 0 95-0
SD 40-3 54 5 42-0 47.9
* Female subjects in luteal phase of menstrual cycle.
Analysis of variance: between sexes NS.
between treatments p<0000004.
sexes x treatments NS.
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was a higher frequency of subjects with no bowel
movements after administration of loperamide with
(five subjects) or without (six subjects) naloxone
compared with placebo (two subjects) or naloxone
(one subject). Borborygmi, pain and abdominal
distension were present in nearly the same
frequency in all treatments. Headache was more
frequent in subjects treated with naloxone alone
(four subjects) or with loperamide (three subjects)
compared with placebo (no subjects) or loperamide
(two subjects) with a statistically significant
difference (p=003) between treatments A and C.
Borborygmi, pain, abdominal distension and
headache always disappeared within eight hours
after the start of the test and were mild and easily
tolerated.
Discussion
Gastrointestinal transit time in rats, assessed by
charcoal test meal, is prolonged by morphine and
this effect is antagonised by naloxone or by its
peripherally selective N-methyl analogue.2 15 These
data are consistent with our findings in man,
showing the increase in transit time induced by the
peripheral opioid agonist loperamide was antagon-
ised by naloxone.
In seven of our eight subjects the administration
of naloxone did not seem to affect the orocaecal
transit time, as previously suggested by similar
results in rats.20 Rees et al reported a modification
by naloxone of the antroduodenal motility pattern in
man,21 but Feldman et al showed that the gastric
emptying of a liquid meal is not influenced by this
drug.4 Moreover, gastric emptying of liquids does
not seem to affect human orocaecal transit time
assessed by lactulose hydrogen breath test.22
In our study the inhibition of the effect of
loperamide by naloxone was obtained by
administering the antagonist by the intravenous
route to avoid the first passage through the liver;
other authors14 reported that naloxone administered
po had an effect on mouth-to-caecum transit time
delayed by hydrolysed gluten, suggesting a possible
purely local effect on the gut.
Lawson et al reported that the orocaecal transit
time in women was significantly longer than in
men.12 This result was not confirmed by our study
probably because of the large inter-individual
variability and the small number of subjects studied.
A possible bias which might increase the intra-
individual variability of the test in women is the
luteal phase of the menstrual cycle which is reported
to prolong transit time. 13 We carried out four of the
16 tests in women in the luteal phase of the
menstrual cycle in order to limit the time between
the four tests in each subject, and the variations
were not so great as to prevent obtaining a
statistically significant result in the group of women.
Our results were obtained using the lactulose
hydrogen breath test, a simple and well tolerated
investigation technique: the side effects reported
were mild, quickly self-limiting and easily tolerated
by the volunteers.
Recently La Brooy et al denied the reproducibility
of the lactulose hydrogen breath test in and between
individuals.'1 We did not study the reproducibility
of the test and no data are available to compare with
La Brooy et al's results. In our experimental
conditions, however, and using each subject as
his-her own control, in accordance with Corbett et
al's previous findings,10 the reproducibility in
individuals of this technique was adequate to detect
the effect of loperamide on mouth-to-caecum transit
time.
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